Purdue Pharma LP, of Stamford, Conn., said the FDA approved Hysingla ER (hydrocodone bitartrate), an extended-release opioid analgesic to treat pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.